Tour of Scotland: Glasgow based Mironid is developing a small molecule to directly target aberrantly high cAMP that causes Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Co-Founder & CEO Neil Wilkie walks us through the biology of ADPKD and explains how Mironid is trying to uniquely directly target it. Plus, the growth of the company, investor support, and being based in Glasgow.